TORC - ResTORbio Is A Risky Bet Ahead Of Phase-III Results
This article was selected to be shared with PRO+ subscribers - find out more here.
Overview
ResTORbio is a Boston, MA company that went public in January 2018. In the aging science community, the company has been closely watched and admired as they are the most mature company targeting the Molecular Target of Rapamyacin ((MTOR)). Early animal studies demonstrated that mTOR inhibitors such as rapapmyacin were capable of drastically extending the life and healthspan of laboratory mice.
mTOR inhibitors are still hyped by many legitimate scientists, hardcore life extension enthusiasts, and investors alike, but